ReForm Biologics
12 Gill Street
Suite 4650
Woburn
Massachusetts
01801
United States
Tel: 617-871-2101
Website: http://reformbiologics.com/
Email: info@reformbiologics.com
About ReForm Biologics
ReForm Biologics is a formulation innovator for protein therapeutics.
Our proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using our platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient to produce. Click here to learn more about these breakthrough technologies.
By enhancing therapeutic protein formulations, ReForm’s technology helps to turn biologic molecules into biobetters in order to improve the patient experience. In addition, our formulation advancements offer an opportunity for extending a product’s lifecycle.
YEAR FOUNDED:
2014
LEADERSHIP:
CEO: John M. Sorvillo Ph.D.
Co-Founder & CTO: David Soane, Ph.D.
CFO: Martha Groves
TECHNOLOGY
Please click here for ReForm Biologics' technology.
CAREER:
Please click here for ReForm Biologics' job opportunities.
24 articles about ReForm Biologics
-
ReForm Biologics Inc. Announces Appointments of Kevin Kavanaugh, CPA, to Chief Financial Officer and Robert Mahoney, PhD, to Chief Scientific Officer
10/13/2021
ReForm Biologics Inc. today announced that Robert Mahoney, PhD, has been promoted to Chief Scientific Officer (CSO) and that Kevin Kavanaugh, CPA, has been promoted to Chief Financial Officer.
-
ReForm Biologics Bolsters Diversity With New Appointments to Board of Directors
9/21/2021
ReForm Biologics, Inc., a company developing a new generation of innovative biologic medicines to improve patient access, safety, and convenience, announced the appointment of four new Directors with significant life science and biotechnology experience: Roopom Banerjee, Kirsten Flowers, Stuart Randle and Edward Sullivan.
-
ReForm Biologics Names Neal Muni, MD, MSPH, Executive Vice President and Chief Operating Officer
9/14/2021
ReForm Biologics , Inc., today announced the appointment of Neal Muni, MD, MSPH, as Executive Vice President and Chief Operating Officer.
-
ReForm Biologics Names Industry Veteran Jeff Hackman as President and Chief Executive Officer
9/8/2021
ReForm Biologics , Inc. today announced the appointment of Jeffrey S. Hackman as President and Chief Executive Officer (CEO).
-
BioSpace Movers & Shakers, Aug. 6
8/6/2021
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers. -
Industry Veteran John Yee, MD, MPH Joins ReForm Biologics Board of Directors
8/3/2021
ReForm Biologics, Inc., a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, announced that John Yee, MD, MPH has joined the company’s Board of Directors.
-
ReForm Biologics Announces Corporate Reorganization
7/21/2021
ReForm Biologics today announced that it has completed a $10 million Series B financing and has restructured to become a C-Corporation.
-
BioSpace Movers & Shakers, March 19
3/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Barbara K. Finck, M.D., Appointed to ReForm Biologics Board of Directors
3/16/2021
Brings 25 years of preclinical and clinical drug development experience to ReForm
-
ReForm Biologics Announces the Issuance of Chinese Patent for Therapeutic Protein Formulations
3/8/2021
ReForm Biologics , a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, announced the expansion of its patent portfolio with issuance of its first patent in China, Patent No. CN ZL20158003.
-
BioSpace Movers & Shakers, Feb. 26
2/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
James Sherblom Appointed Board Chairman to Lead ReForm Biologics’ New Business Strategy
2/25/2021
ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve patient access, safety and convenience. As well, James (Jim) Sherblom has joined the board of directors of ReForm as chairman to lead the shift in strategy.
-
ReForm Biologics Announces the Issuance of U.S. and Japanese Patents for Therapeutic Protein Formulations
4/9/2020
ReForm Biologics , a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent portfolio with the issuance of U.S. Patent No. 10,610,600 and its first patent in Japan, Japanese Patent No. 6674910. The U.S. patent, entitled “Stabilizing Excipients for Therapeutic Protein Formulations,” provides ReForm exclusive rights to therapeutic pr
-
ReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization
2/10/2020
Feb. 10, 2020 12:30 UTC WOBURN, Mass.--( BUSINESS WIRE )-- ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma today announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Under the agreement,
-
ReForm Biologics Announces Issuance of U.S. Patent on Additional Excipients for Therapeutic Protein Formulations
11/20/2019
ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 10,478,498 (the ‘498 patent)
-
ReForm Biologics Announces Two New Technology Presentations at Bioprocessing Summit 2019
8/5/2019
Presentations on bio-layer interferometry for improved formulation screening and use of new excipients to prevent particle formation
-
ReForm Biologics Announces the Appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to Scientific Advisory Board
5/29/2019
ReForm Biologics announced the appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to the company’s Scientific Advisory Board (SAB).
-
ReForm Biologics Announces An Evaluation Agreement for Enhancing Formulation of Two Clinical-stage Pipeline Programs
5/14/2019
ReForm Biologics announced a new customer. ReForm will perform feasibility studies for Bayer AG utilizing its innovative biotherapeutic technologies.
-
ReForm Biologics Announces Issuance of U.S. Patent on Stabilizing Excipients for Therapeutic Protein Formulations
5/8/2019
New class of excipients offers a promising alternative to polysorbates for stabilizing proteins
-
ReForm Biologics Announces New Patent on Surfactant Replacement Excipients to Stabilize Antibody-Based Therapeutics
7/11/2018
New surfactant replacement offers a promising alternative to polysorbates for stabilizing proteins.